SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABSW

SAB Biotherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$2.60+0.07 (+2.77%)

Close on Oct 19, 2026

Market cap: $207.36M
P/E (TTM): –
Dividend yield: –

SAB Biotherapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	0	1.32	2.24	24	61	55
Research & Development	34	30	17	36	57	28
General & Administrative	15	14	24	16	17	6.77
Operating Expenses	49	44	40	53	74	35
Operating Income	-49	-43	-38	-29	-13	21
Interest Expense	0.24	0.32	0.32	0.30	0.29	0.47
Interest & Investment Income	1.43	1.29	0.58	0.07	0.02	0.03
Other Non-Operating Income	62	8.81	-4.12	10	0.01	0.00
Asset Impairment Charges	0	0	0	0	0	0
Gain (Loss) on Investments	0.07	0.03	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	-0.04	0.02	0.01	0.00
Pretax Income	13	–	-42	-19	-17	20
Income Tax Expense	0	0	0	0.03	0	0
Net Income	13	-34	-42	-19	-17	20
Net Income to Common	4.26	-34	-42	-19	–	20
EPS (Basic)(per share)	0.22	-3.68	-7.64	-4.31	-3.57	4.48
EPS (Diluted)(per share)	-0.79	-3.68	-7.64	-4.31	-3.57	4.19
Shares Outstanding (Basic, Weighted)(shares)	19	9.26	5.52	4.35	4.82	4.48
Shares Outstanding (Diluted, Weighted)(shares)	61	9.26	5.52	4.35	4.82	4.77
EBITDA	-46	-38	-34	-26	-12	21

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 15.0%

Financial strength

Current ratio: 9.22
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 70.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.97
Dividend yield: –